Cargando…
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
BACKGROUND: Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762734/ https://www.ncbi.nlm.nih.gov/pubmed/36543718 http://dx.doi.org/10.1016/j.ebiom.2022.104402 |
_version_ | 1784852923697594368 |
---|---|
author | Liew, Felicity Talwar, Shubha Cross, Andy Willett, Brian J. Scott, Sam Logan, Nicola Siggins, Matthew K. Swieboda, Dawid Sidhu, Jasmin K. Efstathiou, Claudia Moore, Shona C. Davis, Chris Mohamed, Noura Nunag, Jose King, Clara Thompson, A.A. Roger Rowland-Jones, Sarah L. Docherty, Annemarie B. Chalmers, James D. Ho, Ling-Pei Horsley, Alexander Raman, Betty Poinasamy, Krisnah Marks, Michael Kon, Onn Min Howard, Luke Wootton, Daniel G. Dunachie, Susanna Quint, Jennifer K. Evans, Rachael A. Wain, Louise V. Fontanella, Sara de Silva, Thushan I. Ho, Antonia Harrison, Ewen Baillie, J. Kenneth Semple, Malcolm G. Brightling, Christopher Thwaites, Ryan S. Turtle, Lance Openshaw, Peter J.M. |
author_facet | Liew, Felicity Talwar, Shubha Cross, Andy Willett, Brian J. Scott, Sam Logan, Nicola Siggins, Matthew K. Swieboda, Dawid Sidhu, Jasmin K. Efstathiou, Claudia Moore, Shona C. Davis, Chris Mohamed, Noura Nunag, Jose King, Clara Thompson, A.A. Roger Rowland-Jones, Sarah L. Docherty, Annemarie B. Chalmers, James D. Ho, Ling-Pei Horsley, Alexander Raman, Betty Poinasamy, Krisnah Marks, Michael Kon, Onn Min Howard, Luke Wootton, Daniel G. Dunachie, Susanna Quint, Jennifer K. Evans, Rachael A. Wain, Louise V. Fontanella, Sara de Silva, Thushan I. Ho, Antonia Harrison, Ewen Baillie, J. Kenneth Semple, Malcolm G. Brightling, Christopher Thwaites, Ryan S. Turtle, Lance Openshaw, Peter J.M. |
author_sort | Liew, Felicity |
collection | PubMed |
description | BACKGROUND: Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when SARS-CoV-2 vaccination was introduced. METHODS: In this follow up study, plasma and nasosorption samples were prospectively collected from 446 adults hospitalised for COVID-19 between February 2020 and March 2021 via the ISARIC4C and PHOSP-COVID consortia. IgA and IgG responses to NP and S of ancestral SARS-CoV-2, Delta and Omicron (BA.1) variants were measured by electrochemiluminescence and compared with plasma neutralisation data. FINDINGS: Strong and consistent nasal anti-NP and anti-S IgA responses were demonstrated, which remained elevated for nine months (p < 0.0001). Nasal and plasma anti-S IgG remained elevated for at least 12 months (p < 0.0001) with plasma neutralising titres that were raised against all variants compared to controls (p < 0.0001). Of 323 with complete data, 307 were vaccinated between 6 and 12 months; coinciding with rises in nasal and plasma IgA and IgG anti-S titres for all SARS-CoV-2 variants, although the change in nasal IgA was minimal (1.46-fold change after 10 months, p = 0.011) and the median remained below the positive threshold determined by pre-pandemic controls. Samples 12 months after admission showed no association between nasal IgA and plasma IgG anti-S responses (R = 0.05, p = 0.18), indicating that nasal IgA responses are distinct from those in plasma and minimally boosted by vaccination. INTERPRETATION: The decline in nasal IgA responses 9 months after infection and minimal impact of subsequent vaccination may explain the lack of long-lasting nasal defence against reinfection and the limited effects of vaccination on transmission. These findings highlight the need to develop vaccines that enhance nasal immunity. FUNDING: This study has been supported by ISARIC4C and PHOSP-COVID consortia. ISARIC4C is supported by grants from the 10.13039/501100000272National Institute for Health and Care Research and the 10.13039/501100000265Medical Research Council. Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research. The PHOSP-COVD study is jointly funded by 10.13039/100014013UK Research and Innovation and National Institute of Health and Care Research. The funders were not involved in the study design, interpretation of data or the writing of this manuscript. |
format | Online Article Text |
id | pubmed-9762734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-97627342022-12-20 SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination Liew, Felicity Talwar, Shubha Cross, Andy Willett, Brian J. Scott, Sam Logan, Nicola Siggins, Matthew K. Swieboda, Dawid Sidhu, Jasmin K. Efstathiou, Claudia Moore, Shona C. Davis, Chris Mohamed, Noura Nunag, Jose King, Clara Thompson, A.A. Roger Rowland-Jones, Sarah L. Docherty, Annemarie B. Chalmers, James D. Ho, Ling-Pei Horsley, Alexander Raman, Betty Poinasamy, Krisnah Marks, Michael Kon, Onn Min Howard, Luke Wootton, Daniel G. Dunachie, Susanna Quint, Jennifer K. Evans, Rachael A. Wain, Louise V. Fontanella, Sara de Silva, Thushan I. Ho, Antonia Harrison, Ewen Baillie, J. Kenneth Semple, Malcolm G. Brightling, Christopher Thwaites, Ryan S. Turtle, Lance Openshaw, Peter J.M. eBioMedicine Articles BACKGROUND: Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving limited insights into mucosal defences that prevent viral replication and onward transmission. We studied nasal and plasma antibody responses one year after hospitalisation for COVID-19, including a period when SARS-CoV-2 vaccination was introduced. METHODS: In this follow up study, plasma and nasosorption samples were prospectively collected from 446 adults hospitalised for COVID-19 between February 2020 and March 2021 via the ISARIC4C and PHOSP-COVID consortia. IgA and IgG responses to NP and S of ancestral SARS-CoV-2, Delta and Omicron (BA.1) variants were measured by electrochemiluminescence and compared with plasma neutralisation data. FINDINGS: Strong and consistent nasal anti-NP and anti-S IgA responses were demonstrated, which remained elevated for nine months (p < 0.0001). Nasal and plasma anti-S IgG remained elevated for at least 12 months (p < 0.0001) with plasma neutralising titres that were raised against all variants compared to controls (p < 0.0001). Of 323 with complete data, 307 were vaccinated between 6 and 12 months; coinciding with rises in nasal and plasma IgA and IgG anti-S titres for all SARS-CoV-2 variants, although the change in nasal IgA was minimal (1.46-fold change after 10 months, p = 0.011) and the median remained below the positive threshold determined by pre-pandemic controls. Samples 12 months after admission showed no association between nasal IgA and plasma IgG anti-S responses (R = 0.05, p = 0.18), indicating that nasal IgA responses are distinct from those in plasma and minimally boosted by vaccination. INTERPRETATION: The decline in nasal IgA responses 9 months after infection and minimal impact of subsequent vaccination may explain the lack of long-lasting nasal defence against reinfection and the limited effects of vaccination on transmission. These findings highlight the need to develop vaccines that enhance nasal immunity. FUNDING: This study has been supported by ISARIC4C and PHOSP-COVID consortia. ISARIC4C is supported by grants from the 10.13039/501100000272National Institute for Health and Care Research and the 10.13039/501100000265Medical Research Council. Liverpool Experimental Cancer Medicine Centre provided infrastructure support for this research. The PHOSP-COVD study is jointly funded by 10.13039/100014013UK Research and Innovation and National Institute of Health and Care Research. The funders were not involved in the study design, interpretation of data or the writing of this manuscript. Elsevier 2022-12-19 /pmc/articles/PMC9762734/ /pubmed/36543718 http://dx.doi.org/10.1016/j.ebiom.2022.104402 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Liew, Felicity Talwar, Shubha Cross, Andy Willett, Brian J. Scott, Sam Logan, Nicola Siggins, Matthew K. Swieboda, Dawid Sidhu, Jasmin K. Efstathiou, Claudia Moore, Shona C. Davis, Chris Mohamed, Noura Nunag, Jose King, Clara Thompson, A.A. Roger Rowland-Jones, Sarah L. Docherty, Annemarie B. Chalmers, James D. Ho, Ling-Pei Horsley, Alexander Raman, Betty Poinasamy, Krisnah Marks, Michael Kon, Onn Min Howard, Luke Wootton, Daniel G. Dunachie, Susanna Quint, Jennifer K. Evans, Rachael A. Wain, Louise V. Fontanella, Sara de Silva, Thushan I. Ho, Antonia Harrison, Ewen Baillie, J. Kenneth Semple, Malcolm G. Brightling, Christopher Thwaites, Ryan S. Turtle, Lance Openshaw, Peter J.M. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination |
title | SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination |
title_full | SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination |
title_fullStr | SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination |
title_full_unstemmed | SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination |
title_short | SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination |
title_sort | sars-cov-2-specific nasal iga wanes 9 months after hospitalisation with covid-19 and is not induced by subsequent vaccination |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762734/ https://www.ncbi.nlm.nih.gov/pubmed/36543718 http://dx.doi.org/10.1016/j.ebiom.2022.104402 |
work_keys_str_mv | AT liewfelicity sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT talwarshubha sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT crossandy sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT willettbrianj sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT scottsam sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT logannicola sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT sigginsmatthewk sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT swiebodadawid sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT sidhujasmink sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT efstathiouclaudia sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT mooreshonac sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT davischris sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT mohamednoura sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT nunagjose sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT kingclara sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT thompsonaaroger sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT rowlandjonessarahl sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT dochertyannemarieb sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT chalmersjamesd sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT holingpei sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT horsleyalexander sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT ramanbetty sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT poinasamykrisnah sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT marksmichael sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT kononnmin sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT howardluke sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT woottondanielg sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT dunachiesusanna sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT quintjenniferk sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT evansrachaela sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT wainlouisev sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT fontanellasara sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT desilvathushani sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT hoantonia sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT harrisonewen sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT bailliejkenneth sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT semplemalcolmg sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT brightlingchristopher sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT thwaitesryans sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT turtlelance sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT openshawpeterjm sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination AT sarscov2specificnasaligawanes9monthsafterhospitalisationwithcovid19andisnotinducedbysubsequentvaccination |